恩扎鲁胺
医学
前列腺癌
雄激素受体
肿瘤科
内科学
总体生存率
化疗
癌症
作者
Howard I. Scher,Karim Fizazi,Fred Saad,Mary‐Ellen Taplin,Cora N. Sternberg,Kurt Miller,Ronald de Wit,Peter F.A. Mulders,Kim N.,Neal D. Shore,Andrew J. Armstrong,Thomas W. Flaig,Aude Fléchon,Paul N. Mainwaring,Mark T. Fleming,John D. Hainsworth,Mohammad Hirmand,Bryan Selby,Lynn Seely,Johann S. de Bono
标识
DOI:10.1056/nejmoa1207506
摘要
Enzalutamide significantly prolonged the survival of men with metastatic castration-resistant prostate cancer after chemotherapy. (Funded by Medivation and Astellas Pharma Global Development; AFFIRM ClinicalTrials.gov number, NCT00974311.).
科研通智能强力驱动
Strongly Powered by AbleSci AI